Latest News

Press release, Gedea strengthens its board.

Gedea Biotech strengthens its Board with extensive commercial expertise to support next phase

Lund, Sweden – November 18, 2025 Gedea Biotech, an innovative Swedish life science company in women’s health, today announced the appointment of…

Nya insikter om de bakteriella biomet, mikrober.

New insights into the vaginal microbiome: Emilia Lahtinen’s industrial PhD journey

At the intersection of academic research and biotech innovation, Emilia Lahtinen is pursuing her industrial PhD as a collaboration between Gedea…

Förpackning pHyph för behandling av bakteriell vaginos.

Gedea Biotech Announces CE-Marking for pHyph: A Novel Antibiotic-Free Treatment for Bacterial Vaginosis

Gedea Biotech Announces CE-Marking for pHyph: A Novel Antibiotic-Free Treatment for Bacterial Vaginosis

PRESSMEDDELANDE Gedea Biotech får patent i USA för att förebygga för tidig födsel.

PRESS RELEASE Gedea Biotech Receives US Patent for Preventing Preterm Birth

Gedea Biotech announced today that the United States Patent and Trademark Office (USPTO) has granted the company’s patent application covering the…

Pressrelease, Hälsoklyftan mellan män och kvinnor.

Closing the Health Gap

On the Iternational Women's Day we want to address the THE WOMEN’S HEALTH GAP


Press Kit

Click to download logos and images.

Gedea Biotech, vit logotyp.
Gedea Biotech, vit logotyp.

Gedea Biotech AB
Medicon Village
Scheeletorget 1
223 81 Lund
Organisation number: 559000-7026  VAT SE559000702601
Sweden

Julie Waras Brogren, CEO
julie.brogren@gedeabiotech.com
073-352 67 63